Hematology
Silvergate has announced the launch of Xatmep (methotrexate) — an oral solution for treating pediatric patients with acute lymphoblastic leukemia.
Silvergate has announced the launch of Xatmep (methotrexate) — an oral solution for treating pediatric patients with acute lymphoblastic leukemia.
Xatmep – for treating acute lymphocytic leukemia in children
Silvergate has announced the launch of Xatmep (methotrexate) – an oral solution for treating pediatric patients with acute lymphoblastic leukemia as part of multistage combination chemotherapy
The drug may also be used for polyarticular juvenile idiopathic arthritis when first-line therapy, including the full dose of nonsteroidal anti-inflammatory drugs, fails to produce the desired effect
Xatmep is the first ready-to-use oral solution of methotrexate, eliminating the need for injections or tablet crushing.
Researchers monitored the processes occurring in the vascular cells of rats that had survived radiation exposure. According to specialists, in such circumstances the body begins to produce large amounts of ACE molecules, and this proliferation stimulates the growth of oxidants — substances that damage vascular walls and the DNA of their cells.
However, the flavonoid dihydroquercetin, which has a pronounced antioxidant effect, was discovered in larch wood. As it turned out, this component can block the activity of ACE molecules and also suppress the action of oxidants that are destructive to blood vessels.
Flavonoids are compounds found in various plants. Research shows that many of them can exhibit antioxidant, anti-allergenic and even anti-cancer properties. The authors of this project assert that larch flavonoids, when tested against flavonoids from several plant sources, proved to be the most powerful healing substances for vascular tissues.
Book a visit — we will pick a convenient time.